Santhera's Raxone shows no efficacy benefit in MS study

ZURICH (Reuters) - Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company.